Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 2Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

Dow Jones2026/07/30 10:59

By:Dow Jones

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.